Lipoprotein apheresis: an established therapeutic modality for homozygous familial hypercholesterolemia patients refractory to PCSK9 inhibitors: a case report and literature review. [PDF]
Thromb JGuan M +6 more
europepmc +3 more sources
Selective apheresis of low-density lipoproteins in a child [PDF]
Medicina, 2007 The case of rear complicated homozygous hypercholesterolemia treated by a direct adsorption of lipoprotein apheresis procedure is presented in this article. In total, 30 sessions of direct adsorption of lipoprotein apheresis were performed on a 14–16-year-old patient from June 2004 to December 2006. Blood flow rate was 30–70 mL/min.
A. Griskevicius +3 more
openalex +4 more sources
Familial Hypercholesterolemia and Lipoprotein Apheresis. [PDF]
J Atheroscler Thromb, 2019 Lipoprotein apheresis has been developed as the treatment for refractory familial hypercholesterolemia (FH) to remove low-density lipoprotein (LDL), which is the main pathogenic factor. Currently, three procedures are available in Japan, including the plasma exchange, double-membrane filtration, and selective LDL adsorption.
Makino H +6 more
europepmc +5 more sources
Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre. [PDF]
Cardiol J, 2019 Mickiewicz A +10 more
europepmc +3 more sources
Treating PAD Patients with Lipoprotein Apheresis. [PDF]
J Atheroscler ThrombHarada-Shiba M.
europepmc +3 more sources
Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. [PDF]
Eur Heart J, 2016 Moriarty PM +15 more
europepmc +3 more sources
Role of lipoprotein apheresis in the management of familial hypercholesterolemia
Global Journal of Transfusion Medicine, 2021 Familial Hypercholesterolemia (FH) is an autosomal dominant disorder due to a congenital absence of low-density lipoprotein receptor (LDL-R) that transports cholesterol-carrying lipoprotein particles into cells.
Shamanna Seshadri Iyengar +5 more
doaj +1 more source
Lipoprotein(a) Lowering-From Lipoprotein Apheresis to Antisense Oligonucleotide Approach. [PDF]
J Clin Med, 2020 It is well-known that elevated lipoprotein(a)—Lp(a)—levels are associated with a higher risk of cardiovascular (CV) mortality and all-cause mortality, although a standard pharmacotherapeutic approach is still undefined for patients with high CV risk dependent on hyperlipoproteinemia(a). Combined with high Lp(a) levels, familial hypercholesterolemia (FH)
Greco MF +5 more
europepmc +6 more sources
Genetic and molecular architecture of familial hypercholesterolemia
Journal of Internal Medicine, Volume 293, Issue 2, Page 144-165, February 2023., 2023 Abstract Atherosclerotic cardiovascular disease is the leading cause of death globally. Despite its important risk of premature atherosclerosis and cardiovascular disease, familial hypercholesterolemia (FH) is still largely underdiagnosed worldwide. It is one of the most frequently inherited diseases due to mutations, for autosomal dominant forms, in ...
Marianne Abifadel, Catherine Boileau
wiley +1 more source
Therapeutic apheresis in kidney diseases: an updated review
Renal Failure, 2022 Besides conventional medical therapies, therapeutic apheresis has become an important adjunctive or alternative therapeutic option to immunosuppressive agents for primary or secondary kidney diseases and kidney transplantation.
Yi-Yuan Chen +4 more
doaj +1 more source